Travere Therapeutics, Inc. (TVTX) income statement
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30711% above fair value
$48.30−1.94 (-3.86%)
Close on Nov 19, 2026Market cap $4.55BP/E –Yield –
Travere Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 98.6%
- Operating margin
- -6.8%
- Net margin
- -7.4%
- Return on equity, FY2026
- -29.4%
Financial strength
- Current ratio
- 4.05
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 77.4%
Valuation
- P/E ratio
- –
- Price to sales
- 7.70
- Price to book
- 185.66
- Dividend yield
- –
See a number that looks wrong?